Sign In
Buy KALA
$3.54
-0.0700 (-1.94%)
At Close: Jun 22, 2026
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
09:09am, Thursday, 25'th Feb 2021
Kala Pharma (KALA) delivered earnings and revenue surprises of -19.57% and -6.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
08:00am, Thursday, 18'th Feb 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for disease
Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy?
01:39pm, Wednesday, 03'rd Feb 2021
Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 20'th Jan 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Comp
Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
08:24pm, Tuesday, 22'nd Dec 2020
Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 18'th Dec 2020
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Comp
The Play On Kala Pharmaceuticals
02:03am, Thursday, 17'th Dec 2020
The Play On Kala Pharmaceuticals
Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference
08:00am, Wednesday, 11'th Nov 2020
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for disease
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2020 Results - Earnings Call Transcript
06:05am, Saturday, 07'th Nov 2020
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2020 Results - Earnings Call Transcript
Why Kala Pharmaceuticals Stock Sank Today
03:38pm, Tuesday, 27'th Oct 2020
Good news from the FDA translated to bad news for Kala's share price.
Neste Oyj (NTOIF) CEO Peter Vanacker on Q3 2020 Results - Earnings Call Transcript
02:20am, Friday, 23'rd Oct 2020
Neste Oyj (OTCPK:NTOIF) Q3 2020 Results Conference Call October 22, 2020 08:00 AM ET Company Participants Juha-Pekka Kekalainen - Investor Relations Peter Vanacker - President & Chief Executive Of
CBTS Partners with Five9 to Launch Comprehensive Intelligent Cloud Contact Center Solution
12:00am, Monday, 19'th Oct 2020
CBTS, a leading technology provider delivering superior business outcomes, is pleased to announce a partnership with Five9 to launch an advanced Cloud
US only region to not return to hotel profitability
04:02pm, Friday, 25'th Sep 2020
Hoteliers outside the U.S. have cause for muffled celebration: Europe, Asia-Pacific and the Middle East all showed positive gross operating profit per | eTurboNews | Trends | Travel News | Hospitality
GAN Limited: Our Favorite Internet Gambling And Sports Betting Stock (NASDAQ:GAN)
05:46am, Thursday, 24'th Sep 2020
This technology services provider for online casinos and sports betting operators is presenting exceptional growth.
Exasol erzielt zahlreiche Top-Platzierungen im BARC The Data Management Survey 20
12:00am, Thursday, 24'th Sep 2020
Die Exasol AG , Hersteller einer leistungsstarken und hoch performanten In-Memory-Analytics-Datenbank belegte im diesjährigen BARC The Data Management
